Cepastat
NDC Package 63736-219-18

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Cepastat is dissolve a lozenge slowly in mouthadults and children 12 years and oldertake up to 2 lozenges every 2 hours as neededchildren 6 to under 12 yearstake up to 1 lozenge every 2 hours; not more than 10 lozenges in 24 hourschildren under 6 yearsask a doctor. Marketed by Insight Pharmaceuticals, this product is identified by NDC 63736-219 and is authorized under FDA application part356.

Identification & Billing

NDC Package Code
63736-219-18
Package Description
18 LOZENGE in 1 BOX
Product Code
63736-219
11-Digit Billing Format
63736021918
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
18 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Cepastat Extra Strength
Dosage Form
-
Usage Information
Dissolve a lozenge slowly in mouthadults and children 12 years and oldertake up to 2 lozenges every 2 hours as neededchildren 6 to under 12 yearstake up to 1 lozenge every 2 hours; not more than 10 lozenges in 24 hourschildren under 6 yearsask a doctor

Regulatory & Marketing

Labeler Name
Insight Pharmaceuticals
FDA Application #
part356
Marketing Category
OTC MONOGRAPH NOT FINAL - A product marketed pursuant to an Over-the-Counter (OTC) Drug Monograph that is not final.
Start Marketing Date
07-07-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63736-219-18 identifies a specific commercial package of 18 lozenge in 1 box of Cepastat Extra Strength, labeled by Insight Pharmaceuticals. This product is billed for "EA" each discreet unit and contains an estimated amount of 18 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Insight Pharmaceuticals on July 07, 2009. The current certification is valid through December 31, 2017.

How is this Insight Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63736021918. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 18 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63736-219-18
11-Digit CMS (5-4-2)
63736-0219-18

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.